Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile - Slideshow

Telix Pharmaceuticals presented Phase 3 results for ProstACT Global, evaluating its prostate cancer therapy’s efficacy and safety in a March 2026 corporate update. The study’s Part 1 data demonstrated statistically significant improvements in progression-free survival, meeting its primary endpoint for metastatic castration-resistant prostate cancer patients. Safety profiles aligned with prior trials, showing manageable adverse effects, with no new toxicity signals reported during the interim analysis. The company highlighted global regulatory submission plans, targeting FDA and EMA approvals by late 2026, pending full dataset validation and Part 2 results. Investor slides emphasized commercial readiness, including manufacturing scale-up and partnerships to support potential market launch upon regulatory greenlights.